<DOC>
	<DOCNO>NCT00856908</DOCNO>
	<brief_summary>The purpose study assess 1 month safety tolerability multiple oral dos AZD1656 patient Type 2 Diabetes Mellitus Treated Insulin</brief_summary>
	<brief_title>Safety Tolerability After Four Weeks Treatment With AZD1656 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>type II diabetes patient , female non childbearing potential Subjects T2DM diagnosis least one year , treat insulin alone insulin combination antidiabetic drug . Subjects must treat insulin last 3 month prior enrolment ( screen ) HbA1c &lt; 11 % enrolment ( screen ) ( HbA1c value accord international Diabetes Control Complications Trial [ DCCT ] standard ) . FPG range 7.0 13.0 mmol/L ( 126 234 mg/dL ) History ischemic heart disease , symptomatic heart failure , stroke , transitory ischemic attack symptomatic peripheral vascular disease Use glitazones , warfarin , amiodarone within 3 month prior enrolment ( screen ) use potent CYP450 inhibitor , eg , ketoconazole macrolide antibiotic within 14 day randomisation . Any clinically significant abnormality identify physical examination , laboratory test ECG , judgment investigator would compromise patient ' safety successful participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Type II Diabetes</keyword>
</DOC>